Targeted therapy for non small cell lung carcinoma: human phase 1 safety and dose escalation studies
Ended Project Grant Awarded Last action
- Award ID
- R44CA162629
- Recipient
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,988,100
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $833,374 | |
| Original award | $1,154,726 |
Quick answers
Who received award R44CA162629?
R44CA162629 was awarded to A&G Pharmaceutical, Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2012.
How much is award R44CA162629 worth?
$1,988,100 has been obligated on R44CA162629.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award